Table 2.
LVPDP, LVEDP, systolic shortening, and infarct size in control, GI, and CP in control and CP hearts preperfused with AMN or CHX
| Group |
Perfusion Time |
Probability Versus Control | Probability Versus GI | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equilibrium (55 min) |
Reperfusion |
|||||||||||||||||
| 100 min | 110 min | 120 min | 150 min | 180 min | 210 min | |||||||||||||
| LVPDP, mmHg | ||||||||||||||||||
| Control | 108.1±2.1 | 105.1±2.5 | 105.4±2.4 | 104.6±2.1 | 101.6±2.6 | 98.6±2.1 | 97.1±2.6 | <0.0001 | ||||||||||
| Control + AMN | 109.3±2.3 | 105.1±1.9 | 104.3±2.7 | 104.7±2.7 | 102.2±2.9 | 99.6±2.5 | 98.7±2.9 | |||||||||||
| Control + CHX | 108.3±2.7 | 104.7±2.6 | 106.6±2.7 | 104.4±2.5 | 101.6±2.3 | 100.3±2.6 | 99.4±2.6 | |||||||||||
| GI | 107.1±1.9 | 48.0±4.4 | 63.1±4.1 | 74.7±3.8 | 78.1±4.4 | 71.9±4.8 | 65.3±4.6 | <0.0001 | ||||||||||
| CP | 104.9±3.2 | 82.4±4.1 | 96.1±4.3 | 101.6±3.6 | 101.1±3.0 | 99.6±2.9 | 99.5±3.2 | <0.0001 | ||||||||||
| CP + AMN | 106.5±1.9 | 81.5±2.7 | 87.5±2.8 | 86.0±2.4 | 87.8±2.8 | 85.7±2.2 | 86.7±2.1 | 0.0012 | ||||||||||
| CP + CHX | 107.8±3.6 | 84.0±4.1 | 85.0±3.2 | 84.3±2.7 | 82.3±3.3 | 83.5±2.8 | 84.5±2.7 | 0.0039 | ||||||||||
| LVEDP, mmHg | ||||||||||||||||||
| Control | 7.3±0.5 | 5.6±0.7 | 5.6±0.9 | 5.7±0.7 | 5.9±0.7 | 5.9±0.6 | 6.0±0.6 | <0.0001 | ||||||||||
| Control + AMN | 7.1±0.6 | 5.7±0.9 | 5.7±1.1 | 5.7±1.3 | 5.7±0.9 | 5.7±0.9 | 5.9±0.7 | |||||||||||
| Control + CHX | 7.3±0.5 | 5.9±0.7 | 5.9±1.3 | 5.7±0.9 | 5.8±0.7 | 5.8±0.7 | 5.9±0.7 | |||||||||||
| GI | 7.3±0.6 | 12.0±2.1 | 11.0±1.7 | 9.0±1.2 | 8.9±0.8 | 8.4±0.8 | 8.9±0.9 | <0.0001 | ||||||||||
| CP | 6.3±0.6 | 6.5±1.2 | 6.0±1.3 | 5.5±1.2 | 6.0±1.1 | 6.4±1.4 | 6.9±1.5 | <0.0001 | ||||||||||
| CP + AMN | 7.7±0.4 | 7.7±0.3 | 6.8±0.3 | 6.8±0.5 | 7.7±0.4 | 8.0±0.6 | 8.5±0.8 | <0.0001 | ||||||||||
| CP + CHX | 7.7±0.2 | 7.3±0.6 | 7.3±0.8 | 7.5±1.0 | 7.8±1.1 | 7.8±1.1 | 7.8±0.9 | <0.0001 | ||||||||||
| Systolic shortening, percentage of equilibrium | ||||||||||||||||||
| Control | 100.0±0.0 | 103.8±1.8 | 100.4±2.1 | 100.0±2.0 | 97.3±2.0 | 98.5±3.5 | 96.4±3.6 | 0.0376 | ||||||||||
| Control + AMN | 100.0±0.0 | 104.7±1.4 | 101.8±2.3 | 99.8±3.1 | 103.7±2.4 | 100.8±3.3 | 96.5±3.6 | |||||||||||
| Control + CHX | 100.0±0.0 | 103.3±1.7 | 103.8±3.8 | 101.6±3.3 | 102.6±2.6 | 99.4±2.8 | 97.9±3.3 | |||||||||||
| GI | 100.0±0.0 | 54.0±9.0 | 68.0±5.6 | 71.6±7.7 | 77.0±5.1 | 74.2±5.2 | 64.5±5.3 | 0.0376 | ||||||||||
| CP | 100.0±0.0 | 78.2±3.1 | 88.1±4.6 | 92.2±5.6 | 99.1±2.6 | 95.1±5.5 | 92.7±4.5 | |||||||||||
| CP + AMN | 100.0±0.0 | 71.2±5.7 | 82.3±5.1 | 88.5±3.3 | 93.1±3.2 | 90.2±3.5 | 87.7±3.5 | |||||||||||
| CP + CHX | 100.0±0.0 | 68.6±5.8 | 86.2±5.9 | 94.2±4.9 | 90.5±5.8 | 89.0±6.3 | 86.1±6.7 | |||||||||||
| Infarct size, percent LV mass | ||||||||||||||||||
| Control | 1.73±0.15 | <0.0001 | ||||||||||||||||
| Control + AMN | 1.95±0.21 | 0.0002 | ||||||||||||||||
| Control + CHX | 1.88±0.17 | <0.0001 | ||||||||||||||||
| GI | 24.18±3.70 | <0.0001 | ||||||||||||||||
| CP | 1.75±0.035 | <0.0001 | ||||||||||||||||
| CP + AMN | 5.75±1.59 | <0.0001 | 0.0006 | |||||||||||||||
| CP + CHX | 6.06±1.61 | <0.0001 | 0.0007 | |||||||||||||||
Values are means ± SE. Left ventricular (LV) peak developed pressure (LVPDP), LV end-diastolic pressure (LVEDP), systolic shortening, and infarct size were determined at the end of preperfusion and during global ischemia (GI) and reperfusion in control, GI, and cardioplegia (CP) hearts and in control, GI, and CP hearts preperfused for 55 min with Krebs-Ringer solution containing α-amanitin (AMN; 2.5 μg/ml) to inhibit RNA synthesis or cycloheximide (CHX; 50 μg/ml) to inhibit protein synthesis. Control, control + AMN, and control + CHX hearts received sham ischemia. There were no significant differences observed within or between for any variable for control, control + AMN, and control + CHX hearts. Statistical comparisons are shown. Significant differences at P < 0.05 are also shown.